These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11398906)

  • 1. Renoprotective therapy in patients with nondiabetic nephropathies.
    Pisoni R; Ruggenenti P; Remuzzi G
    Drugs; 2001; 61(6):733-45. PubMed ID: 11398906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of antihypertensive drugs.
    Preston RA
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):19S-32S. PubMed ID: 10077416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of calcium antagonists in chronic kidney disease.
    Gashti CN; Bakris GL
    Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):155-61. PubMed ID: 15202609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
    Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression.
    Benigni A; Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):1-6. PubMed ID: 11195041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies.
    Ruggenenti P
    Semin Nephrol; 2004 Mar; 24(2):158-67. PubMed ID: 15017528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitors and the kidney. A risk-benefit assessment.
    Navis G; Faber HJ; de Zeeuw D; de Jong PE
    Drug Saf; 1996 Sep; 15(3):200-11. PubMed ID: 8879974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.
    Bos H; Andersen S; Rossing P; De Zeeuw D; Parving HH; De Jong PE; Navis G
    Kidney Int Suppl; 2000 Apr; 75():S32-7. PubMed ID: 10828759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and treatment of hypertension and renal disease.
    Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):571-8. PubMed ID: 9818206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).
    Remuzzi G; Chiurchiu C; Ruggenenti P
    Kidney Int Suppl; 2004 Nov; (92):S90-6. PubMed ID: 15485427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.